| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10052256 | The Journal of Urology | 2005 | 5 Pages |
Abstract
PPB offers acceptable 12-year BFR in patients who present with clinically localized prostate cancer. Implant dosimetry continues as an important predictor for BFR, while the addition of adjuvant therapies such as hormones and external radiation are insignificant. In patients who experience biochemical failure it appears that PSA doubling time is an important predictor of survival.
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
LOUIS POTTERS, CAROL MORGENSTERN, EMIL CALUGARU, PAUL FEARN, ANUP JASSAL, JOSEPH PRESSER, EDWARD MULLEN,